MedTrace Logo

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

NCT00147498 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2013-01-30

Study results available
· View outcomes & findings →

Summary

The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily \[BID\]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).

Conditions

Interventions

DRUG

CP-690,550

Oral tablets administered at a dose of 5 mg BID for 6 weeks

DRUG

CP-690,550

Oral tablets administered at a dose of 15 mg BID for 6 weeks

DRUG

CP-690,550

30 mg BID for 6 weeks

OTHER

Placebo

Placebo tablets

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • United States
  • Belgium
  • Brazil
  • Canada
  • Germany
  • Italy
  • Mexico
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00147498 on ClinicalTrials.gov